FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108808878> ?p ?o ?g. }

• W2108808878 abstract "The X-linked bleeding disorder haemophilia A is due to a deficiency or functional defect of coagulation factor VIII. The bleeding tendency can be corrected by administration of factor VIII concentrates. A serious complication of factor VIII replacement therapy is the development of anti-factor VIII antibodies (inhibitors) that neutralize factor VIII activity. In recent years, the epitope-specifities and the inhibitory mechanisms of factor VIII inhibitors have gained increasing interest. The generation of factor VIII knock-out mice has opened the possibility of studying the immunobiology of inhibitor formation in murine models of haemophilia A. In spite of these recent developments however, the immunological mechanisms underlying the anti-factor VIII immune response have remained poorly understood so far. Most of our current knowledge is based on studies on inhibitor formation in the severe form of haemophilia. However, inhibitors also occur in patients with mild haemophilia A, in particular after a period of extensive factor VIII replacement therapy. These patients differ from severe haemophiliacs in that they have low levels of circulating factor VIII activity (5-25% of normal). The presence of endogenous factor VIII may have major impact on the immune response to exogenous factor VIII during replacement therapy. The studies presented in this thesis were performed to obtain a better understanding of the immunobiology of inhibitor development in mild haemophilia A. In the introduction (chapter 1), recent studies on the immunobiology of factor VIII inhibitors in haemophilia A patients are summarized and discussed. We have characterized the anti-factor VIII antibodies in patients with mild haemophilia A employing phage display technology. In chapter 2, anti-C2 antibodies were isolated and characterized from the repertoire of a mild haemophilia A patient. Our results provide evidence for the presence of two classes of anti-C2 antibodies that recognize distinct antigenic sites in factor VIII. The characteristics of the anti-C2 antibodies were further analysed in chapter 3, and compared to the epitopes of previously described murine monoclonal antibodies. The first class of anti-C2 antibodies bind to the epitope defined by monoclonal antibody ESH4. The second class of antibodies bind to the epitope defined by monoclonal antibody CLB-CAg 117. Antibodies belonging to this second class of antibodies were also isolated from a different patient with mild haemophilia A (chapter 4). The VH gene segment usage of the antibodies directed at the epitope defined by CLB-CAg 117 is less restricted compared to the first class of anti-C2 antibodies. Based on the long CDR3 region, we argue that this second class of antibodies originates from a pool of polyreactive human antibodies.In chapter 5, we describe the inhibitor development of a patient with mild haemophilia A caused by an Arg593 to Cys mutation. We have isolated and characterized anti-A2 antibodies using phage display and we have performed epitope-mapping studies of anti-factor VIII antibodies in plasma using immunoprecipitation analysis. The data presented in chapter 5 provide a possible explanation for anamnestic responses observed in patients with a history of inhibitor development. We propose that activation of a quiescent pool of memory B cells underlies the rise in inhibitor titer observed in haemophilia A patients with a history of inhibitor development. Chapter 6 describes the epitope specificities of anti-factor VIII antibodies in another patient from our cohort of mild haemophilia A patients with the Arg593 to Cys mutation. Results from this chapter and previous studies show that high responder patients with the Arg593 to Cys substitution develop inhibitory antibodies predominantly directed at the A2 domain of factor VIII. This suggests that inhibitor formation proceeds via a common mechanism in these patients. The role of HLA class II alleles in inhibitor formation was investigated by HLA genotyping of 42 patients with the Arg593 to Cys mutation. Our data suggest a weak association between inhibitor development and HLA class II alleles in mild haemophilia A patients with the Arg593 to Cys mutation.In Chapter 7, we present the characteristics of a mouse transgenic for human factor VIII with the Arg593 to Cys mutation (hufVIII-R593C mouse). The anti-factor VIII immune response was analysed in transgenic hufVIII-R593C mice crossed with factor VIII-deficient mice (exon 16 knock out, or E-16 KO mice). Serial intravenous injections of human factor VIII do not evoke an immune response in hufVIII-R593C/E-16 KO mice. The introduction of the human factor VIII–R593C transgene renders the mice tolerant to human factor VIII. However, when hufVIII-R593C/E-16 KO mice were subcutaneously injected with factor VIII in the presence of an adjuvant, loss of tolerance to factor VIII was observed. The results of chapter 7 demonstrate that hufVIII-R593C/E-16 KO mice provide a valuable model for studies directed at the mechanisms underlying inhibitor development in haemophilia A.Finally, chapter 8 provides a general overview that discusses the implications of our findings." @default.
• W2108808878 created "2016-06-24" @default.
• W2108808878 creator A5047042371 @default.
• W2108808878 date "2003-05-22" @default.
• W2108808878 modified "2023-09-24" @default.
• W2108808878 title "Factor VIII inhibitors in mild haemophilia A" @default.
• W2108808878 cites W120923871 @default.
• W2108808878 cites W1482422136 @default.
• W2108808878 cites W1493718410 @default.
• W2108808878 cites W1512481003 @default.
• W2108808878 cites W1513178664 @default.
• W2108808878 cites W1519546700 @default.
• W2108808878 cites W1528709070 @default.
• W2108808878 cites W1548584593 @default.
• W2108808878 cites W1555988808 @default.
• W2108808878 cites W1556343014 @default.
• W2108808878 cites W1564224388 @default.
• W2108808878 cites W1572321656 @default.
• W2108808878 cites W1575105525 @default.
• W2108808878 cites W157872429 @default.
• W2108808878 cites W1599481463 @default.
• W2108808878 cites W1599562890 @default.
• W2108808878 cites W1599771874 @default.
• W2108808878 cites W1700997260 @default.
• W2108808878 cites W1754568015 @default.
• W2108808878 cites W1806817428 @default.
• W2108808878 cites W1879113090 @default.
• W2108808878 cites W1882920556 @default.
• W2108808878 cites W1888325444 @default.
• W2108808878 cites W1891870091 @default.
• W2108808878 cites W1900908265 @default.
• W2108808878 cites W1929159186 @default.
• W2108808878 cites W1957247581 @default.
• W2108808878 cites W1964975805 @default.
• W2108808878 cites W1969821102 @default.
• W2108808878 cites W1970579419 @default.
• W2108808878 cites W1971743740 @default.
• W2108808878 cites W1974991654 @default.
• W2108808878 cites W1977971077 @default.
• W2108808878 cites W1978803404 @default.
• W2108808878 cites W1978812129 @default.
• W2108808878 cites W1987319546 @default.
• W2108808878 cites W1987953408 @default.
• W2108808878 cites W1988197572 @default.
• W2108808878 cites W1988868730 @default.
• W2108808878 cites W1989105808 @default.
• W2108808878 cites W1990828666 @default.
• W2108808878 cites W1991526219 @default.
• W2108808878 cites W1995380127 @default.
• W2108808878 cites W1998614164 @default.
• W2108808878 cites W1998675277 @default.
• W2108808878 cites W1999519260 @default.
• W2108808878 cites W2002886319 @default.
• W2108808878 cites W2003131026 @default.
• W2108808878 cites W2003301767 @default.
• W2108808878 cites W2007797448 @default.
• W2108808878 cites W2010425787 @default.
• W2108808878 cites W2013285346 @default.
• W2108808878 cites W2020034788 @default.
• W2108808878 cites W2020475165 @default.
• W2108808878 cites W2020732854 @default.
• W2108808878 cites W2026502021 @default.
• W2108808878 cites W20271833 @default.
• W2108808878 cites W2030898001 @default.
• W2108808878 cites W2031263707 @default.
• W2108808878 cites W2034293576 @default.
• W2108808878 cites W2035064373 @default.
• W2108808878 cites W2035772332 @default.
• W2108808878 cites W2041049082 @default.
• W2108808878 cites W2041309682 @default.
• W2108808878 cites W2048182307 @default.
• W2108808878 cites W2052218777 @default.
• W2108808878 cites W2052394880 @default.
• W2108808878 cites W2052860396 @default.
• W2108808878 cites W2053128936 @default.
• W2108808878 cites W2056881674 @default.
• W2108808878 cites W2066321540 @default.
• W2108808878 cites W2067977668 @default.
• W2108808878 cites W2071801576 @default.
• W2108808878 cites W2075248695 @default.
• W2108808878 cites W2076258597 @default.
• W2108808878 cites W2079220 @default.
• W2108808878 cites W2079833943 @default.
• W2108808878 cites W2082897488 @default.
• W2108808878 cites W2083445427 @default.
• W2108808878 cites W2083645573 @default.
• W2108808878 cites W2086196796 @default.
• W2108808878 cites W2086703018 @default.
• W2108808878 cites W2088251038 @default.
• W2108808878 cites W2091629117 @default.
• W2108808878 cites W2105041057 @default.
• W2108808878 cites W2105056822 @default.
• W2108808878 cites W2109128853 @default.
• W2108808878 cites W2112592916 @default.
• W2108808878 cites W2114099152 @default.
• W2108808878 cites W2117085497 @default.
• W2108808878 cites W2119333315 @default.
• W2108808878 cites W2120876654 @default.
• W2108808878 cites W212667147 @default.
• W2108808878 cites W2128653791 @default.

• next